Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adaptimmune Therapeutics plc ADAP

Healthcare Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include... see more

Recent & Breaking News (NDAQ:ADAP)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR

PR Newswire March 28, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR

PR Newswire March 23, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR

PR Newswire March 16, 2023

INVESTIGATION ALERT: Halper Sadeh LLC Investigates RADI, ADAP, TCRR, ROCC

PR Newswire March 7, 2023

ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders

Business Wire March 6, 2023

Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update

Newsfile March 6, 2023

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Newsfile March 6, 2023

Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023

Newsfile February 22, 2023

Adaptimmune Announces Changes to Board of Directors

Newsfile February 16, 2023

Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma

Newsfile January 9, 2023

Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma

Newsfile December 23, 2022

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

Newsfile November 18, 2022

Adaptimmune Reports Third-Quarter Financial Results and Business Update

Newsfile November 8, 2022

Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers

Newsfile November 8, 2022

Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022

Newsfile October 27, 2022

Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK

Newsfile October 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adaptimmune Therapeutics plc - ADAP

Newsfile September 17, 2022

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

Newsfile September 9, 2022

Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials

Newsfile August 25, 2022

Adaptimmune Reports Second-Quarter Financial Results and Business Update

Newsfile August 4, 2022